sorafenib has been researched along with piplartine in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (piplartine) | Trials (piplartine) | Recent Studies (post-2010) (piplartine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 298 | 2 | 261 |
| Protein | Taxonomy | sorafenib (IC50) | piplartine (IC50) |
|---|---|---|---|
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | 7 | |
| Thioredoxin reductase 1, cytoplasmic | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, A; Chen, M; Chen, W; Fang, S; Ji, J; Kong, C; Qiao, E; Shu, G; Weng, Q; Xu, S; Zhang, D; Zhao, Z; Zheng, L | 1 |
1 other study(ies) available for sorafenib and piplartine
| Article | Year |
|---|---|
Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cleavage And Polyadenylation Specificity Factor; Dioxolanes; Humans; Liver Neoplasms; Reactive Oxygen Species; Sorafenib | 2022 |